Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Identifieur interne : 000C44 ( Main/Exploration ); précédent : 000C43; suivant : 000C45Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Auteurs : Vibeke Strand [États-Unis] ; Sophie Dimonaco [Royaume-Uni] ; Katie Tuckwell [États-Unis] ; Micki Klearman [États-Unis] ; Neil Collinson [Royaume-Uni] ; John H. Stone [États-Unis]Source :
- Arthritis research & therapy [ 1478-6362 ] ; 2019.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anti-inflammatoires (usage thérapeutique), Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (usage thérapeutique), Artérite à cellules géantes (physiopathologie), Artérite à cellules géantes (psychologie), Artérite à cellules géantes (traitement médicamenteux), Association de médicaments, Enquêtes et questionnaires, Fatigue (physiopathologie), Fatigue (psychologie), Fatigue (traitement médicamenteux), Femelle, Humains, Mâle, Méthode en double aveugle, Prednisone (administration et posologie), Prednisone (usage thérapeutique), Qualité de vie, Résultat thérapeutique, Sujet âgé, État de santé.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Prednisone.
- physiopathologie : Artérite à cellules géantes, Fatigue.
- psychologie : Artérite à cellules géantes, Fatigue.
- traitement médicamenteux : Artérite à cellules géantes, Fatigue.
- usage thérapeutique : Anti-inflammatoires, Anticorps monoclonaux humanisés, Prednisone.
- Adulte d'âge moyen, Association de médicaments, Enquêtes et questionnaires, Femelle, Humains, Mâle, Méthode en double aveugle, Qualité de vie, Résultat thérapeutique, Sujet âgé, État de santé.
English descriptors
- KwdEn :
- Aged, Anti-Inflammatory Agents (therapeutic use), Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Fatigue (drug therapy), Fatigue (physiopathology), Fatigue (psychology), Female, Giant Cell Arteritis (drug therapy), Giant Cell Arteritis (physiopathology), Giant Cell Arteritis (psychology), Health Status, Humans, Male, Middle Aged, Prednisone (administration & dosage), Prednisone (therapeutic use), Quality of Life, Surveys and Questionnaires, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Prednisone.
- chemical , therapeutic use : Anti-Inflammatory Agents, Antibodies, Monoclonal, Humanized, Prednisone.
- drug therapy : Fatigue, Giant Cell Arteritis.
- physiopathology : Fatigue, Giant Cell Arteritis.
- psychology : Fatigue, Giant Cell Arteritis.
- Aged, Double-Blind Method, Drug Therapy, Combination, Female, Health Status, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Treatment Outcome.
Abstract
Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) every week or every other week and prednisone tapering achieved superior rates of sustained remission to patients treated with placebo and prednisone tapering in a randomised controlled trial. Health-related quality of life (HRQOL) in patients from this trial is now reported.
DOI: 10.1186/s13075-019-1837-7
PubMed: 30786937
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000490
- to stream PubMed, to step Curation: 000490
- to stream PubMed, to step Checkpoint: 000458
- to stream Ncbi, to step Merge: 001E14
- to stream Ncbi, to step Curation: 001E14
- to stream Ncbi, to step Checkpoint: 001E14
- to stream Main, to step Merge: 000C44
- to stream Main, to step Curation: 000C44
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.</title><author><name sortKey="Strand, Vibeke" sort="Strand, Vibeke" uniqKey="Strand V" first="Vibeke" last="Strand">Vibeke Strand</name><affiliation wicri:level="2"><nlm:affiliation>Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dimonaco, Sophie" sort="Dimonaco, Sophie" uniqKey="Dimonaco S" first="Sophie" last="Dimonaco">Sophie Dimonaco</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd., Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd., Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Tuckwell, Katie" sort="Tuckwell, Katie" uniqKey="Tuckwell K" first="Katie" last="Tuckwell">Katie Tuckwell</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Klearman, Micki" sort="Klearman, Micki" uniqKey="Klearman M" first="Micki" last="Klearman">Micki Klearman</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Collinson, Neil" sort="Collinson, Neil" uniqKey="Collinson N" first="Neil" last="Collinson">Neil Collinson</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd., Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd., Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Stone, John H" sort="Stone, John H" uniqKey="Stone J" first="John H" last="Stone">John H. Stone</name><affiliation wicri:level="1"><nlm:affiliation>Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Yawkey 2, 55 Fruit Street, Boston, MA, 02114, USA. jhstone@mgh.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Yawkey 2, 55 Fruit Street, Boston, MA, 02114</wicri:regionArea><wicri:noRegion>02114</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30786937</idno><idno type="pmid">30786937</idno><idno type="doi">10.1186/s13075-019-1837-7</idno><idno type="wicri:Area/PubMed/Corpus">000490</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000490</idno><idno type="wicri:Area/PubMed/Curation">000490</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000490</idno><idno type="wicri:Area/PubMed/Checkpoint">000458</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000458</idno><idno type="wicri:Area/Ncbi/Merge">001E14</idno><idno type="wicri:Area/Ncbi/Curation">001E14</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E14</idno><idno type="wicri:Area/Main/Merge">000C44</idno><idno type="wicri:Area/Main/Curation">000C44</idno><idno type="wicri:Area/Main/Exploration">000C44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.</title><author><name sortKey="Strand, Vibeke" sort="Strand, Vibeke" uniqKey="Strand V" first="Vibeke" last="Strand">Vibeke Strand</name><affiliation wicri:level="2"><nlm:affiliation>Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dimonaco, Sophie" sort="Dimonaco, Sophie" uniqKey="Dimonaco S" first="Sophie" last="Dimonaco">Sophie Dimonaco</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd., Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd., Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Tuckwell, Katie" sort="Tuckwell, Katie" uniqKey="Tuckwell K" first="Katie" last="Tuckwell">Katie Tuckwell</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Klearman, Micki" sort="Klearman, Micki" uniqKey="Klearman M" first="Micki" last="Klearman">Micki Klearman</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Collinson, Neil" sort="Collinson, Neil" uniqKey="Collinson N" first="Neil" last="Collinson">Neil Collinson</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd., Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd., Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Stone, John H" sort="Stone, John H" uniqKey="Stone J" first="John H" last="Stone">John H. Stone</name><affiliation wicri:level="1"><nlm:affiliation>Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Yawkey 2, 55 Fruit Street, Boston, MA, 02114, USA. jhstone@mgh.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Yawkey 2, 55 Fruit Street, Boston, MA, 02114</wicri:regionArea><wicri:noRegion>02114</wicri:noRegion></affiliation></author></analytic><series><title level="j">Arthritis research & therapy</title><idno type="eISSN">1478-6362</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Fatigue (drug therapy)</term><term>Fatigue (physiopathology)</term><term>Fatigue (psychology)</term><term>Female</term><term>Giant Cell Arteritis (drug therapy)</term><term>Giant Cell Arteritis (physiopathology)</term><term>Giant Cell Arteritis (psychology)</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prednisone (administration & dosage)</term><term>Prednisone (therapeutic use)</term><term>Quality of Life</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Artérite à cellules géantes (physiopathologie)</term><term>Artérite à cellules géantes (psychologie)</term><term>Artérite à cellules géantes (traitement médicamenteux)</term><term>Association de médicaments</term><term>Enquêtes et questionnaires</term><term>Fatigue (physiopathologie)</term><term>Fatigue (psychologie)</term><term>Fatigue (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Prednisone (administration et posologie)</term><term>Prednisone (usage thérapeutique)</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>État de santé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Prednisone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antibodies, Monoclonal, Humanized</term><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fatigue</term><term>Giant Cell Arteritis</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Artérite à cellules géantes</term><term>Fatigue</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Fatigue</term><term>Giant Cell Arteritis</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Artérite à cellules géantes</term><term>Fatigue</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Fatigue</term><term>Giant Cell Arteritis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Artérite à cellules géantes</term><term>Fatigue</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Anticorps monoclonaux humanisés</term><term>Prednisone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Surveys and Questionnaires</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>État de santé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) every week or every other week and prednisone tapering achieved superior rates of sustained remission to patients treated with placebo and prednisone tapering in a randomised controlled trial. Health-related quality of life (HRQOL) in patients from this trial is now reported.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Strand, Vibeke" sort="Strand, Vibeke" uniqKey="Strand V" first="Vibeke" last="Strand">Vibeke Strand</name></region><name sortKey="Klearman, Micki" sort="Klearman, Micki" uniqKey="Klearman M" first="Micki" last="Klearman">Micki Klearman</name><name sortKey="Stone, John H" sort="Stone, John H" uniqKey="Stone J" first="John H" last="Stone">John H. Stone</name><name sortKey="Tuckwell, Katie" sort="Tuckwell, Katie" uniqKey="Tuckwell K" first="Katie" last="Tuckwell">Katie Tuckwell</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Dimonaco, Sophie" sort="Dimonaco, Sophie" uniqKey="Dimonaco S" first="Sophie" last="Dimonaco">Sophie Dimonaco</name></noRegion><name sortKey="Collinson, Neil" sort="Collinson, Neil" uniqKey="Collinson N" first="Neil" last="Collinson">Neil Collinson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30786937
|texte= Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30786937" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |